Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3

View at publisher
Authors: Paul Wheatley‐Price, Nofisat Ismaila, Antonio Calles, Jeremy Cetnar, Terri Conneran, Parth Anil Desai, Greg Andrew Durm, Hidehito Horinouchi, Humera Khurshid, Swati Kulkarni, Kristen Ashley Marrone, Kirstin Perdrizet
+1 more Lyudmila A. Bazhenova
Cited by: 1
References: 8

Abstract

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website .

Fields of Study & Subjects

Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Lung Cancer Research Studies

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Pages
101200JCO2601958–101200JCO2601958
Publication date
17 August 2026
Language
EN